Chromogenic in situ hybridization

J. M.S. Bartlett; Fiona M. Campbell; Merdol Ibrahim; Peter Wencyk; Ian Ellis; Elaine Kay; Yvonne Connolly; Anthony O'Grady; Silvana Di Palma; Jane Starczynski; John M. Morgan; Bharat Jasani; Keith Miller

doi:10.1309/AJCPXY3MJ6GSRCYP

Chromogenic in situ hybridization

J. M.S. Bartlett, Fiona M. Campbell, Merdol Ibrahim, Peter Wencyk, Ian Ellis, Elaine Kay, Yvonne Connolly, Anthony O'Grady, Silvana Di Palma, Jane Starczynski, John M. Morgan, Bharat Jasani, Keith Miller

School of Medicine

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization test and report on concordance of silver in situ hybridization (SISH) data with fluorescence in situ hybridization (FISH) data and on intraobserver and interlaboratory scoring consistency. HER2 results were scored from 45 breast cancers in 7 laboratories using the Ventana (Tucson, AZ) INFORM HER-2 SISH assay and in 1 central laboratory using a standard FISH assay. Overall, 94.8% of cases were successfully analyzed by SISH across the 6 participating laboratories that reported data. Concordance for diagnosis of HER2 amplification by SISH compared with FISH was high (96.0% overall). Intraobserver variability (8.0%) and intersite variability (12.66%) of absolute HER2/chromosome 17 ratios appear to be tightly controlled across all 6 participating laboratories. The Ventana INFORM HER-2 SISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national guidelines for performance of diagnostic tests.

Original language	English
Pages (from-to)	514-520
Number of pages	7
Journal	American Journal of Clinical Pathology
Volume	132
Issue number	4
DOIs	https://doi.org/10.1309/AJCPXY3MJ6GSRCYP
Publication status	Published - Oct 2009

Keywords

Amplification
Breast
Chromogenic in situ hybridization
Consistency
Fluorescence in situ hybridization
HER2
Intersite
Intraobserver
Silver in situ hybridization
UK National External Quality Assessment Scheme

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1309/AJCPXY3MJ6GSRCYP

Fingerprint Dive into the research topics of 'Chromogenic in situ hybridization'. Together they form a unique fingerprint.

Cite this

Chromogenic in situ hybridization. / Bartlett, J. M.S.; Campbell, Fiona M.; Ibrahim, Merdol; Wencyk, Peter; Ellis, Ian; Kay, Elaine; Connolly, Yvonne; O'Grady, Anthony; Di Palma, Silvana; Starczynski, Jane; Morgan, John M.; Jasani, Bharat; Miller, Keith.

In: American Journal of Clinical Pathology, Vol. 132, No. 4, 10.2009, p. 514-520.

Research output: Contribution to journal › Article › peer-review

@article{8b70d6c0a76e4cd5a2ba63711738a59c,

title = "Chromogenic in situ hybridization",

abstract = "Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization test and report on concordance of silver in situ hybridization (SISH) data with fluorescence in situ hybridization (FISH) data and on intraobserver and interlaboratory scoring consistency. HER2 results were scored from 45 breast cancers in 7 laboratories using the Ventana (Tucson, AZ) INFORM HER-2 SISH assay and in 1 central laboratory using a standard FISH assay. Overall, 94.8% of cases were successfully analyzed by SISH across the 6 participating laboratories that reported data. Concordance for diagnosis of HER2 amplification by SISH compared with FISH was high (96.0% overall). Intraobserver variability (8.0%) and intersite variability (12.66%) of absolute HER2/chromosome 17 ratios appear to be tightly controlled across all 6 participating laboratories. The Ventana INFORM HER-2 SISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national guidelines for performance of diagnostic tests.",

keywords = "Amplification, Breast, Chromogenic in situ hybridization, Consistency, Fluorescence in situ hybridization, HER2, Intersite, Intraobserver, Silver in situ hybridization, UK National External Quality Assessment Scheme",

author = "Bartlett, {J. M.S.} and Campbell, {Fiona M.} and Merdol Ibrahim and Peter Wencyk and Ian Ellis and Elaine Kay and Yvonne Connolly and Anthony O'Grady and {Di Palma}, Silvana and Jane Starczynski and Morgan, {John M.} and Bharat Jasani and Keith Miller",

year = "2009",

month = oct,

doi = "10.1309/AJCPXY3MJ6GSRCYP",

language = "English",

volume = "132",

pages = "514--520",

journal = "American Journal of Clinical Pathology",

issn = "0002-9173",

publisher = "American Society of Clinical Pathologists",

number = "4",

}

TY - JOUR

T1 - Chromogenic in situ hybridization

AU - Bartlett, J. M.S.

AU - Campbell, Fiona M.

AU - Ibrahim, Merdol

AU - Wencyk, Peter

AU - Ellis, Ian

AU - Kay, Elaine

AU - Connolly, Yvonne

AU - O'Grady, Anthony

AU - Di Palma, Silvana

AU - Starczynski, Jane

AU - Morgan, John M.

AU - Jasani, Bharat

AU - Miller, Keith

PY - 2009/10

Y1 - 2009/10

N2 - Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization test and report on concordance of silver in situ hybridization (SISH) data with fluorescence in situ hybridization (FISH) data and on intraobserver and interlaboratory scoring consistency. HER2 results were scored from 45 breast cancers in 7 laboratories using the Ventana (Tucson, AZ) INFORM HER-2 SISH assay and in 1 central laboratory using a standard FISH assay. Overall, 94.8% of cases were successfully analyzed by SISH across the 6 participating laboratories that reported data. Concordance for diagnosis of HER2 amplification by SISH compared with FISH was high (96.0% overall). Intraobserver variability (8.0%) and intersite variability (12.66%) of absolute HER2/chromosome 17 ratios appear to be tightly controlled across all 6 participating laboratories. The Ventana INFORM HER-2 SISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national guidelines for performance of diagnostic tests.

AB - Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization test and report on concordance of silver in situ hybridization (SISH) data with fluorescence in situ hybridization (FISH) data and on intraobserver and interlaboratory scoring consistency. HER2 results were scored from 45 breast cancers in 7 laboratories using the Ventana (Tucson, AZ) INFORM HER-2 SISH assay and in 1 central laboratory using a standard FISH assay. Overall, 94.8% of cases were successfully analyzed by SISH across the 6 participating laboratories that reported data. Concordance for diagnosis of HER2 amplification by SISH compared with FISH was high (96.0% overall). Intraobserver variability (8.0%) and intersite variability (12.66%) of absolute HER2/chromosome 17 ratios appear to be tightly controlled across all 6 participating laboratories. The Ventana INFORM HER-2 SISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national guidelines for performance of diagnostic tests.

KW - Amplification

KW - Breast

KW - Chromogenic in situ hybridization

KW - Consistency

KW - Fluorescence in situ hybridization

KW - HER2

KW - Intersite

KW - Intraobserver

KW - Silver in situ hybridization

KW - UK National External Quality Assessment Scheme

UR - http://www.scopus.com/inward/record.url?scp=70349575948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349575948&partnerID=8YFLogxK

U2 - 10.1309/AJCPXY3MJ6GSRCYP

DO - 10.1309/AJCPXY3MJ6GSRCYP

M3 - Article

C2 - 19762528

AN - SCOPUS:70349575948

VL - 132

SP - 514

EP - 520

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -